Background/Aims Liver function deterioration during treatment with tyrosine kinase inhibitors (TKIs) affects overall survival (OS) prognosis in patients with advanced hepatocellular carcinoma (HCC). This study aimed to monitor the dynamic changes in the albumin-bilirubin (ALBI) score to assess liver function deterioration during first-line treatment with sorafenib or lenvatinib and to evaluate its prognostic value for OS.
Methods A retrospective cohort study was conducted on 73 patients with unresectable advanced HCC who received lenvatinib or sorafenib from 2022 to 2025 at Ho Chi Minh City Oncology Hospital, Vietnam. Changes in the ALBI score were recorded monthly and analyzed using the Wilcoxon signed-rank test. Cox regression models were used to identify factors affecting OS and progression-free survival (PFS), which were analyzed using the Kaplan-Meier method, stratified by ALBI grade.
Results During the 6 month follow-up period, the median ALBI score increased significantly compared with baseline (p<0.05), indicating liver function deterioration. This deterioration was observed in both patients with progressive disease (ALBI increased from -2.64 to -2.02; p<0.0001) and those with stable disease (ALBI increased from -2.77 to -2.46; p=0.003). The median OS was 13 months, with significant differences according to baseline ALBI grade (grade 1: 16 months; grade 2a: 10 months; grade 2b: 8 months; p = 0.042). The baseline ALBI grade also had prognostic value for PFS in the sorafenib subgroup (p = 0.032). The change in ALBI score (ΔALBI) at month 3 was an independent prognostic factor for OS (p=0.032). Grade ≥3 toxicity was most frequent in the ALBI grade 2b group, with toxicity rates increasing with worsening ALBI grade (p=0.012).
Conclusion The ALBI score is a valuable tool for dynamically monitoring liver function and prognosticating survival in HCC patients receiving first-line TKI therapy. The observed decline in liver function suggests a composite effect of tumor progression and treatment-related toxicity.
The current Food and Drug Administration-approved systemic treatments for advanced hepatocellular carcinoma (HCC) include multikinase inhibitors (tyrosine kinase inhibitor [TKI]) and immune checkpoint inhibitors (ICIs). Among ICIs, nivolumab is used as secondline therapy for advanced HCC after sorafenib failure or patient intolerance. In this case, a patient with infiltrative HCC and portal vein tumor thrombosis was treated with hepatic arterial infusion chemotherapy (HAIC) and radiation therapy. New lung metastasis developed after HAICs; thus, lenvatinib treatment was initiated. However, the disease progressed. Thereafter, sorafenib treatment was initiated but he developed intolerance, with grade 3 sorafenib-related diarrhea. Subsequently, nivolumab was administered as rescue therapy. He demonstrated a partial response to nivolumab after the third treatment and viable HCCs in the lungs and liver completely disappeared after the 24th treatment. These findings suggest that nivolumab could be used as an effective rescue therapy for advanced HCC progression after TKI treatment.
Citations
Citations to this article as recorded by
Intermediate-stage (BCLC stage B) infiltrative hepatocellular carcinoma: safety and efficacy of chemoembolization Seong Ho Kim, Jin Hyoung Kim, Gun Ha Kim, Ji Hoon Kim, Heung-Kyu Ko, Hee Ho Chu, Ji Hoon Shin, Dong Il Gwon, Gi-Young Ko, Hyun-Ki Yoon, Shakir Aljerdah, Nayoung Kim European Radiology.2023; 33(12): 8736. CrossRef
The pathogenesis of hepatocellular carcinoma (HCC) is a complex process. During the last decade, advances in genomic technologies enabled delineation of the genomic landscape of HCC, resulting in the identification of the common underlying molecular alterations. The tumor microenvironment, regulated by inflammatory cells, including cancer cells, stromal tissues, and the surrounding extracellular matrix, has been extensively studied using molecular data. The integration of molecular, immunological, histopathological, and clinical findings has provided clues to uncover predictive biomarkers to enhance responses to novel therapies. Herein, we provide an overview of the current HCC genomic landscape, previously identified gene signatures that are used routinely to predict prognosis, and an immune-specific class of HCC. Since biomarker-driven treatment is still an unmet need in HCC management, translation of these discoveries into clinical practice will lead to personalized therapies and improve patient care, especially in the era of targeted and immunotherapies.
Citations
Citations to this article as recorded by
RNA-based therapies for colorectal cancer: targeting the β-catenin pathway via microbiota -modulated miRNAs Rajkumar Prabhakaran, Ramkumar Muthu, Rajkumar Manickam, Venkatesh Subramanian, Karthikeyan Mahendran Frontiers in Molecular Biosciences.2026;[Epub] CrossRef
Clinical performance of GAAD score, alpha-fetoprotein, and PIVKA-II in diagnosing hepatocellular carcinoma in the Vietnamese cohort Thuy Thi Thu Pham, Dat Tan Ho, Toan Bao Nguyen, Hai Thanh Phan Discover Oncology.2025;[Epub] CrossRef
Comprehensive clinicopathologic study of alpha fetoprotein‐expression in a large cohort of patients with hepatocellular carcinoma Dirk Andreas Ridder, Arndt Weinmann, Mario Schindeldecker, Lana Louisa Urbansky, Kristina Berndt, Tiemo Sven Gerber, Hauke Lang, Johannes Lotz, Karl J. Lackner, Wilfried Roth, Beate Katharina Straub International Journal of Cancer.2022; 150(6): 1053. CrossRef
Two distinct stem cell‐like subtypes of hepatocellular carcinoma with clinical significance and their therapeutic potentials Sung Hwan Lee, Yun Seong Jeong, Sunyoung Lee, Bo Hwa Sohn, Ho Kyoung Hwang, Gi Hong Choi, Chang Moo Kang, Jin Sub Choi, Woo Jung Lee, Jae‐Ho Cheong, Hee Jin Jang, Ahmed Kaseb, Lewis Roberts, Sun Young Yim, Yun Shin Chun, Ju‐Seog Lee Cancer Communications.2022; 42(2): 179. CrossRef
Activated TAZ induces liver cancer in collaboration with EGFR/HER2 signaling pathways Hyuk Moon, Hyunjung Park, Min Jee Chae, Hye Jin Choi, Do Young Kim, Simon Weonsang Ro BMC Cancer.2022;[Epub] CrossRef
Tumor aggressiveness is independent of radiation quality in murine hepatocellular carcinoma and mammary tumor models Eshwar B. Udho, Shane M. Huebner, Dawn M. Albrecht, Kristina A. Matkowskyj, Linda Clipson, Catigan A. Hedican, Rachel Koth, Santina M. Snow, Emily L. Eberhardt, Devon Miller, Rachel Van Doorn, Genti Gjyzeli, Erin K. Spengler, Douglas R. Storts, Douglas H. International Journal of Radiation Biology.2021; 97(8): 1140. CrossRef
Infiltrative hepatocellular carcinoma with multiple lung metastasis completely cured using nivolumab: a case report Ji Eun Han, Hyo Jung Cho, Soon Sun Kim, Jae Youn Cheong Journal of Liver Cancer.2021; 21(2): 169. CrossRef
Update on Hepatocellular Carcinoma: a Brief Review from Pathologist Standpoint Nese Karadag Soylu Journal of Gastrointestinal Cancer.2020; 51(4): 1176. CrossRef
Hepatocellular carcinoma: new provisions of the WHO classification, 5th edition, 2019 E.M. Nepomnyashchaya, A.V. Shaposhnikov, E.A. Yurieva Arkhiv patologii.2020; 82(6): 36. CrossRef
A 54-year old man diagnosed with advanced hepatocellular carcinoma began treatment with sorafenib. After 3 weeks of treatment, he complained of abdominal pain and nausea. Abdominal sonography showed multiple hepatic lesions only. Serum amylase and lipase levels were 35 U/L and 191 U/L, respectively. The patient was diagnosed with sorafenib-induced acute pancreatitis. After 10 days of discontinuing sorafenib he still complained of nausea and loss of appetite. Esophagogastroduodenoscopy showed a large bulging lesion, which was suspected to cause extrinsic compression on the high body of the gastric anterior wall. Computed tomography scan revealed a cystic lesion, 8.3 cm in size, in the pancreatic tail, suggesting a pancreatic pseudocyst. After the withdrawal of sorafenib, systemic chemotherapy with Adriamycin and cisplatin was administered. Four months after the discontinuation of sorafenib, the size of the pancreatic pseudocyst decreased from 8.3 cm to 3 cm. The patient's symptoms were also relieved.